# Why two approval records describe different ingredients

- Article ID: research-327
- Product: SEMA / IGF-1 LR3 (sema-igf-1-lr3-708, sema-igf-1-lr3-709)
- Canonical page: https://heritagebiolabs.com/research-library/articles/327-why-two-approval-records-describe-different-ingredients
- Product collection: https://heritagebiolabs.com/research-library/products/sema-igf-1-lr3
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-708
- Product page: https://heritagebiolabs.com/product/sema-igf-1-lr3-709
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2023, 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids connected by peptide bonds. Some mimic hormones that carry signals between tissues. Semaglutide is a modified peptide that activates the GLP-1 receptor. IGF-1 LR3 is an engineered, extended version of the insulin-like growth factor 1 protein. This entry names both molecules together. FDA records help answer which active ingredients and clinical uses have actually been evaluated for approved products. [1, 2, 3]

The U.S. Wegovy label identifies semaglutide as the active ingredient and describes separate indications for its tablets and injection. It specifies populations and outcomes such as long-term weight management or cardiovascular risk reduction. The injectable product also has a defined liver disease indication under accelerated approval. These approvals apply to the forms and uses set out in that label. [1]

A different U.S. label identifies mecasermin as the active ingredient of Increlex. Mecasermin is recombinant human IGF-1. Its approved use concerns growth failure in specified pediatric patients with severe primary IGF-1 deficiency or a defined growth hormone gene deletion and antibodies. IGF-1 LR3 has an altered sequence and is studied as a distinct research material. A label for mecasermin therefore cannot establish how the LR3 variant would behave. [2, 3]

The approval documents also concern separate products. A search of PubMed and ClinicalTrials.gov identified no controlled human study that administered the exact semaglutide and IGF-1 LR3 pair. To evaluate a combination, researchers would need evidence about the actual interventions studied together, including their formulation, outcomes and adverse events. The two approved product labels provide information about their named ingredients and indications. They supply no such comparison for the catalog pair. [1, 2, 3]

## Sources

1. U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Drugs@FDA (publication 2026-06). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf>
2. U.S. Food and Drug Administration. INCRELEX (mecasermin) injection, prescribing information. Drugs@FDA (publication 2025-07). <https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021839s033lbl.pdf>
3. Z. Lu et al. Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Applied Microbiology and Biotechnology (publication 2023-06). <https://pubmed.ncbi.nlm.nih.gov/37261455/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 066 - Selank and SEMA IGF-1 LR3.docx; article 327; content SHA-256 6928f9ddde7c37d6f90ba96eadfd9ebd7f0ec1fd3d37616dbb8e6b81bc351836.
